Literature DB >> 17190648

The role of death receptor ligands in shaping tumor microenvironment.

Theresa L Whiteside1.   

Abstract

Death receptor ligands (FasL, TRAIL) activate apoptosis in cells expressing the cognate receptors. Evidence suggests that these ligands also deliver pro-inflammatory signals. In the tumor microenvironment, "Fas counterattack" mounted by tumors against immune cells is mediated by tumor-associated FasL. But death ligands crosslinking their receptors also induce inhibition of apoptosis and activation of the transcription factor, NFkappaB, with a subsequent burst of pro-inflammatory cytokine production and tumor growth promotion. NFkappaB, a key link between inflammation and cancer, regulates dual activities of death ligands, depending on molecular signals in the tumor microenvironment. This paper focuses on death ligands as an example of the extensive repertoire of strategies devised by tumors for escape from immune control.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17190648     DOI: 10.1080/08820130600991893

Source DB:  PubMed          Journal:  Immunol Invest        ISSN: 0882-0139            Impact factor:   3.657


  16 in total

1.  Polymorphisms of the FAS and FASL genes and risk of breast cancer.

Authors:  Wenmin Wang; Zhongqiu Zheng; Wenjie Yu; Hui Lin; Binbin Cui; Feilin Cao
Journal:  Oncol Lett       Date:  2011-12-28       Impact factor: 2.967

Review 2.  Vaccines versus immunotherapy: overview of approaches in deciding between options.

Authors:  Angus G Dalgleish
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 3.  The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment.

Authors:  Gregory K Pennock; Laura Q M Chow
Journal:  Oncologist       Date:  2015-06-11

4.  Cytoplasmic overexpression of CD95L in esophageal adenocarcinoma cells overcomes resistance to CD95-mediated apoptosis.

Authors:  Gregory A Watson; Sanjay Naran; Xinglu Zhang; Michael T Stang; Pierre E Queiroz de Oliveira; Steven J Hughes
Journal:  Neoplasia       Date:  2011-03       Impact factor: 5.715

5.  Spontaneous apoptosis of tumor-specific tetramer+ CD8+ T lymphocytes in the peripheral circulation of patients with head and neck cancer.

Authors:  Andreas E Albers; Carsten Schaefer; Carmen Visus; William Gooding; Albert B DeLeo; Theresa L Whiteside
Journal:  Head Neck       Date:  2009-06       Impact factor: 3.147

6.  Retinoic acid morpholine amide (RAMA) inhibits expression of Fas ligand through EP1 receptor in colon cancer cells.

Authors:  Shao-Xuan Chen; Shi-Yu Du; Yun-Ting Wang; Hong-Chuan Zhao; Yan-Li Zhang; Li Yao
Journal:  Tumour Biol       Date:  2015-07-27

Review 7.  Immune responses to malignancies.

Authors:  Theresa L Whiteside
Journal:  J Allergy Clin Immunol       Date:  2010-01-12       Impact factor: 10.793

Review 8.  Prognostic Role of Programmed Death Ligand-1 Expression in Breast Cancer: A Systematic Review and Meta-Analysis.

Authors:  Xue Li; Minghuan Li; Zhen Lian; Hui Zhu; Li Kong; Ping Wang; Jinming Yu
Journal:  Target Oncol       Date:  2016-12       Impact factor: 4.493

9.  The role of MAPK-ERK pathway in 67-kDa laminin receptor-induced FasL expression in human cholangiocarcinoma cells.

Authors:  Shi-Gang Duan; Long Cheng; Da-Jiang Li; Jin Zhu; Yan Xiong; Xiao-Wu Li; Shu-Guang Wang
Journal:  Dig Dis Sci       Date:  2010-01-26       Impact factor: 3.199

Review 10.  T cell-tumor interaction directs the development of immunotherapies in head and neck cancer.

Authors:  A E Albers; L Strauss; T Liao; T K Hoffmann; A M Kaufmann
Journal:  Clin Dev Immunol       Date:  2010-12-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.